Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Q4 Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231129:nRSc9865Ua&default-theme=true

RNS Number : 9865U  Benchmark Holdings PLC  29 November 2023

29 November 2023

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

Q4 Results

(3 months ended 30 September 2023)

 

Good operational performance and positive outlook in all business areas

Results affected by market factors in the period

 

In compliance with the terms of the Company's unsecured green bond which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the 3
months ended 30 September 2023 (the "period"). All Q4 FY23 and Q4 FY22 figures
quoted in this announcement are based on unaudited accounts.

 

This morning the Company published its full year audited results for the 12
months ended 30 September 2023 which can be found
on https://www.benchmarkplc.com/investors
(https://www.benchmarkplc.com/investors)

 

Q4 FY23 Financial highlights

·      Revenues from continuing operations of £36.6m, 14% below the
prior year (-7% CER):

·    Genetics - strong performance in salmon egg sales against an
exceptionally strong Q4 FY22 which benefitted from supply constraints in the
market; revenues were 6% below Q4 FY22 (+2% CER)

·    Advanced Nutrition - strong performance against a backdrop of
challenging conditions in the global shrimp markets; revenues were 9% below
the prior year (-3% CER)

·    Health - revenues were 53% below Q4 FY22 (-50% CER) reflecting a
delay in the peak season for sea lice treatments in Norway; the Company has
experienced an increase in Ectosan® Vet and CleanTreat® sales post
period-end

·      Adjusted EBITDA from continuing operations excluding fair value
movements from biological assets £9.2m (Q4 FY22: £10.2m)

·      Adjusted EBITDA margin from continuing operations excluding fair
value movements marginally increased to 25% (Q4 FY22: 24%)

·      Cash and cash equivalents of £29.3m and available liquidity of
£41.5m as at 27th November

Operational highlights

·       Launch of first AI-enabled tool, Snapp-Art which enables
customers to count and qualify Artemia accurately and efficiently,
contributing to customer productivity

·       Integration of salmon activities under the leadership of Geir
Olav Meningen, Head of Genetics, and integration and reorganisation of shrimp
activities under the leadership of Patrick Waty, Head of Advanced Nutrition.
This is an important strategic step which creates significant opportunities
for commercial synergies and efficiencies

·       Obtained MSC (Marine Stewardship Council) certification for the
Artemia harvested from the Great Salt Lakes

·       Divestment of tilapia breeding business; maintaining our
presence in tilapia genetics through Genetics Services

 

Current trading and outlook - positive momentum trading in-line with
management expectations

 

·      Good start to the year and positive momentum in all business
areas

·    Good visibility of revenues in salmon genetics

·    Early indications of improvement in the shrimp markets

·    Increase in sea lice treatments post period end with good capacity
utilisation of CleanTreat®; expect normal seasonality

·    Continue to strengthen our unique position in an industry that is
structurally growing driven by megatrends

 £m                                                                            Q4 FY23  Q4 FY22       % AER  % CER(**)  FY23          FY22

                                                                                        restated(*)                     (full year)   restated(*)
 Revenue from continuing operations                                            36.6     42.4          -14%   -7%        169.5         157.7
 Adjusted
 Adjusted EBITDA(1) from continuing operations                                 7.4      9.4           -21%   -15%       35.5          32.6
 Adj. EBITDA excluding fair value movements from biological assets             9.2      10.2          -10%   -4%        35.6          31.0
 Adjusted Operating Profit excluding fair value uplift from biological assets  3.9      5.0           -23%   -14%       14.7          9.2
 Statutory
 Operating (loss)/profit from continuing operations                            (2.3)    (1.1)                           (5.3)         (6.2)
 Loss before tax from continuing operations                                    (7.3)    (6.1)         19%    17%        (12.7)        (21.4)
 Loss for the Period                                                           (9.2)    (8.2)         -13%   -13%       (16.1)        (28.7)
 Basic loss per share (p)                                                      (1.87)   (1.36)                          (3.16)        (4.60)
 Net debt(3)                                                                   (65.5)   (73.7)                          (65.5)        (73.7)
 Net debt excluding lease liabilities                                          (45.6)   (47.5)                          (45.6)        (47.4)

 

* 2022 figures have been restated to reflect changes to the ongoing continuing
business during the year following the disposal of the tilapia business

**  Constant exchange rate (CER) figures derived by retranslating current
year figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
and disposal related expenditure.

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition and disposal related items and amortisation of
intangible assets excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

Business Area Summary (continuing operations)*

 £m                                                              Q4 FY23  Q4 FY22    % AER  % CER(**)  FY23          FY22

                                                                          restated                     (full year)   restated
 Revenue
 Advanced Nutrition                                              17.1     18.9       -9%    -3%        78.5          80.3
 Genetics                                                        16.9     18.0       -6%    2%         65.5          57.4
 Health                                                          2.6      5.6        -53%   -50%       25.5          20.1
 Adjusted EBITDA(1)
 Advanced Nutrition                                              3.5      4.7        -26%   -20%       18.4          19.0
 Genetics                                                        5.4      6.1        -11%   -5%        15.7          17.4
 -       Net of fair value movements in biological assets        7.2      6.9        4%     10%        15.8          15.8
 Health                                                          (0.9)    0.6                          4.8           0.1

 

* 2022 figures have been restated to reflect changes to the ongoing continuing
business during the year following the disposal of the tilapia business

**  Constant exchange rate (CER) figures derived by retranslating current
year figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
and disposal related expenditure.

 

Enquiries

 

 For further information, please contact:
 Benchmark Holdings plc                         Tel:  0114 240 9939
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Deutsche Numis (Broker and NOMAD)              Tel:  020 7260 1000
 Freddie Barnfield, Duncan Monteith, Sher Shah

 MHP                                            Tel:  020 3128 8100

Katie Hunt, Reg Hoare
 
                   benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)

 

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia, in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

Management Report

 

Q4 FY23 financial results were soft compared to the prior year but overall the
Group performed well, maintaining momentum and commercial focus, and is well
positioned for the year ahead. In Advanced Nutrition, prevailing conditions in
the shrimp markets continued to impact demand for our products and revenues in
the period. In Health we experienced low activity for Ectosan® Vet and
CleanTreat® treatments with customers delaying use of our solution compared
to last year, as they assessed the severity of sea lice in their farms. Post
period-end we have seen increased use. Performance in Genetics was solid but
comparatively behind Q4 FY22 which benefitted from bumper demand for our
salmon eggs as a result of supply constraints in the market.  Together, these
factors led to Group revenues from continuing operations of £36.6m, 14%
behind the prior year (-7% CER).

 

Despite high inflationary pressure, operating costs in Q4 FY23 were £10.9m,
17% below the prior year (Q4 FY22: £13.1m) due to the timing of some of the
variable costs in the year and ongoing cost control.  Furthermore, Q4 FY23
has seen the benefit of some of the restructuring of our cost base in Health
and Advanced Nutrition.  Further details are given in the business area
narrative below.  R&D expenses were £1.6m, 20% below the prior year
driven by a reduction in Genetics R&D in the period.

 

Adjusted EBITDA from continuing operations for the quarter was £7.4m, 21%
below the prior year (Q4 FY22: £9.4m) primarily as a result of lower sales,
partially offset by a reduction in operating costs. Excluding fair value
movements from biological assets, Adjusted EBITDA from continuing operations
was £9.2m, 10% below the prior year. Our Adjusted EBITDA margin excluding
fair value movements was 25%, marginally ahead of the prior year.

 

Advanced Nutrition

 

Q4 FY23 revenues in Advanced Nutrition were £17.1m, 9% behind the prior year
(Q4 FY22: £18.9m) (-3% CER) due to weak shrimp markets as set out above.
 By product segment, revenue from Diets was £8.0m (Q4 FY22: £8.5m) followed
by Artemia £7.0m (Q4 FY22: £8.2m) and Health £2.1m (Q4 FY22: £2.4m).

 

Adjusted EBITDA of £3.5m was 26% lower than the prior year (Q4
FY22: £4.7m) primarily due to lower sales, lower infringement fees and
higher bad debt provisions. Operating costs of £5.9m were 5% down Q4 FY22 (up
2% CER). R&D expenses totalled £0.7m (Q4 FY22: £0.6m). The Adjusted
EBITDA margin was 20% (Q4 FY22: 25%).

 

Despite the comparatively soft performance against last year, the continued
commercial focus and efficiencies implemented in FY23 mean that our Advanced
Nutrition business will emerge stronger from a period of weakness in the
shrimp market. We have further strengthened our market position and continued
to innovate as evidenced by the launch of our first AI-enabled tool. Our
dedicated technical support team in our local markets which help our customers
optimise the use of our products has been instrumental to our commercial
effort and will help drive future growth.

 

Genetics

 

Revenues from continuing operations in the period were £16.9m, 6% behind
prior year (Q4 FY22: £18.0m) (+2% CER). While salmon egg volume of 84
million was 8 million lower than the prior year, this represents a strong
performance against an exceptional Q4 FY22 when we experienced very high
demand due a supply shortage in the market.  Harvest revenues were £1.8m
higher than the prior year driven by higher volumes harvested in the quarter.
Shrimp revenues at £0.3m were £0.4m behind prior year (Q4 FY22: £0.7m) as
we continue to work on the development of the next generation of products.

 

Adjusted EBITDA from continuing operations was £5.4m, 11% lower than the
prior year (Q4 FY22: £6.1m) primarily due to lower sales. However, adjusted
EBITDA from continuing operations excluding the fair value movements from
biological assets was £7.2m, 4% ahead of the prior year (Q4
FY22: £6.9m).  As a result, the Adjusted EBITDA margin excluding biological
asset movements increased to 43% (Q4 FY22: 38%).

 

By species, despite lower egg sales, salmon delivered an excellent performance
with Adjusted EBITDA of £6.3m (Q4 FY22: £6.7m) and after fair value
movements of £8.1m (Q4 FY22: 7.6m). In shrimp, lower revenues led to a
higher Adjusted EBITDA loss of £0.9m (Q4 FY22: loss of £0.6m) and tilapia,
now discontinued, delivered an Adjusted EBITDA loss before exceptional items
of £0.3m (Q4 FY22: loss of £0.7m).

 

Health

 

Performance in Health was affected by low levels of sea lice treatments in the
period which impacted revenues and resulted in low capacity utilisation of our
CleanTreat® infrastructure.  Revenues were £2.6m (Q4 FY22: £5.6m).
 Adjusted EBITDA in the period was a loss of £0.9m (Q4 FY22: £0.6m). Post
period end we have experienced increased demand for Ectosan® Vet and
CleanTreat® and we have good visibility for Q1 FY24. Beyond Q1 FY24 we expect
normal seasonality. Operating costs were 23% below the prior year at £1.4m
(Q4 FY22: £1.8m) partially as a result of efficiencies resulting from the
integration of the salmon activities across Health and Genetics. R&D
expenses were flat against the prior year at £0.1m.  Costs associated with
the leases of the vessels for the CleanTreat® units amounted to £1.9m.

 

Sales of Salmosan® Vet in the period were £1.0m, 34% behind prior year (Q4
FY22: £1.6m).  The drop is driven by the timing of orders in one of our key
markets while the rest of the regions reported growth in the period.

 

Finance costs, cashflow and net debt

 

Net finance cost for the quarter of £5.0m are in line with the prior year (Q4
FY22: £5.0m).  Movements in the quarter in the fair value of our financial
instruments taken out to hedge our external borrowings caused a charge of
£1.6m, (Q4 FY22: £5.3m).  Interest charges for the period of £3.0m (Q4
FY22: £4.2m) reflected higher interest charges being more than offset by
lower amortisation of deferred financing costs and a one-off fee for early
settlement upon refinancing in Q4 FY22.  These lower finance costs were
offset by foreign exchange movements which led to a foreign exchange loss of
£0.2m compared to a gain of £5.4m in Q4 FY22.

 

Positive operating cashflows from strong trading in the quarter and tight cost
control left the Group with cash balances of £36.5m at the end of the period
(Q4 FY22: £36.4m).  This left net debt at the quarter end at £65.5m (Q4
FY22: £73.7m).  Net debt excluding lease liabilities was £45.6m (Q4 FY22:
£47.5m).

 

Outlook

 

We have had a good start to the year and there is good momentum in the
business. We have good visibility of sales in Genetics at normalised levels
following the supply shortage experienced Q1 FY23. In Advanced Nutrition we
are seeing early signs of recovery in the shrimp markets which we expect will
contribute positively from Q2 FY24 onwards. Our CleanTreat® units are
currently operating at a good capacity utilisation and we expect this to be
reflected in Q1 FY24. We expect normal seasonality with low treatment volumes
in the second half. We are considering actions to optimise our operations and
cashflow during the transition to an integrated customer solution. The
continued integration and streamlining of the Group will enable us to further
leverage the Group capabilities and drive efficiencies contributing to a
positive outlook for the year ahead.

 

Looking into the future, we are uniquely positioned in an industry that is
structurally growing. With a clear strategy addressing the main aquaculture
species, we have significant opportunity to deliver growth and shareholder
returns. We will continue the development of the Group and ongoing
consideration of our strategy to realise the value inherent in our business
for the benefit of all our stakeholders.

 All figures in £000's                                                Notes  Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated*
(unaudited)
Restated*

(unaudited)
(audited)
 Revenue                                                              4      36,591        42,448        169,476       157,707
 Cost of sales                                                               (16,674)      (17,895)      (82,726)      (73,777)
 Gross profit                                                                19,917        24,553        86,750        83,930
 Research and development costs                                              (1,592)       (1,991)       (6,069)       (6,634)
 Other operating costs                                                       (10,865)      (13,124)      (45,157)      (44,095)
 Share of (loss)/profit of equity-accounted investees, net of tax            (33)          (57)          (32)          (595)
 Adjusted EBITDA²                                                            7,427         9,381         35,492        32,606
 Exceptional - restructuring, acquisition and disposal related items  6      (686)         (423)         (3,904)       16
 EBITDA¹                                                                     6,741         8,958         31,588        32,622
 Depreciation and impairment                                                 (4,769)       (4,588)       (18,409)      (19,692)
 Amortisation and impairment                                                 (4,265)       (5,440)       (18,495)      (19,161)
 Operating loss                                                              (2,293)       (1,070)       (5,316)       (6,231)
 Finance cost                                                         7      (6,602)       (12,229)      (15,048)      (19,893)
 Finance income                                                       7      1,643         7,219         7,670         4,741
 Loss before taxation                                                        (7,252)       (6,080)       (12,694)      (21,383)
 Tax on loss                                                          8      (1,958)       (2,074)       (3,365)       (7,268)
 Loss from continuing operations                                             (9,210)       (8,154)       (16,059)      (28,651)
 Discontinued operations
 Loss from discontinued operations, net of tax                        5      (4,333)       (715)         (5,505)       (1,800)
                                                                             (13,543)      (8,869)       (21,564)      (30,451)
 Loss for the year attributable to:
 - Owners of the parent                                                      (13,853)      (9,561)       (23,146)      (32,087)
 - Non-controlling interest                                                  310           692           1,582         1,636
                                                                             (13,543)      (8,869)       (21,564)      (30,451)

 Earnings per share
 Basic loss per share (pence)                                         9      (1.87)        (1.36)        (3.16)        (4.60)
 Diluted loss per share (pence)                                       9      (1.87)        (1.36)        (3.16)        (4.60)
 Earnings per share - continuing operations
 Basic loss per share (pence)                                         9      (1.29)        (1.26)        (2.41)        (4.34)
 Diluted loss per share (pence)                                       9      (1.29)        (1.26)        (2.41)        (4.34)

 Adjusted EBITDA from continuing operations                                  7,427         9,381         35,492        32,606
 Adjusted EBITDA from discontinued operations                                (335)         (623)         (1,254)       (1,425)
 Total Adjusted EBITDA                                                       7,092         8,758         34,238        31,181

 

1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment

2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items

* 2022 numbers have been restated to reflect certain operations of the Group
that have been classified as discontinued operations    during the period
in line with IFRS 5

 

 

 

 

 All figures in £000's                                                                                       Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
(unaudited)
(unaudited)
(audited)

 Loss for the period                                                                                         (13,543)      (8,869)       (21,564)      (30,451)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                                                    11,691        23,225        (23,475)      47,606
 Cash flow hedges - changes in fair value                                                                    773           2,047         (2,123)       2,627
 Cash flow hedges - reclassified to profit or loss                                                           (1,501)       2,387         2,623         2,546
 Total comprehensive income for the period                                                                   (2,580)       18,790        (44,539)      22,328

 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                                                      (3,154)       18,109        (45,404)      20,326
 - Non-controlling interest                                                                                  574           681           865           2,002
                                                                                                             (2,580)       18,790        (44,539)      22,328

 Total comprehensive income for the period attributable to owners of the
 parent:
 - Continuing operations                                                                                     1,128         18,277        (39,777)      21,509
 - Discontinued operations*                                                                                  (4,282)       (168)         (5,627)       (1,183)
                                                                                                             (3,154)       18,109        (45,404)      20,326

 

* Total comprehensive income for the period relating to discontinued
operations for Q4 2023 includes the loss of £4,333,000 (Q4 2022: £715,000)
and foreign exchange gain of £51,000 (Q4 2022: £547,000). FY23 includes the
loss of £5,505,000 (2022: £1,800,000) and foreign exchange loss of £122,000
(2022: gain of £617,000).

 

The accompanying notes are an integral part of this consolidated financial
information.

 

                                                                          30 September 2023  30 September 2022
 All figures in £000's                                             Notes  (unaudited)        (audited)
 Assets
 Property, plant and equipment                                            73,411             81,900
 Right-of-use assets                                                      19,804             27,034
 Intangible assets                                                        206,077            245,264
 Equity-accounted investees                                               3,558              3,113
 Other investments                                                        14                 15
 Biological and agricultural assets                                       18,406             20,878
 Non-current assets                                                       321,270            378,204
 Inventories                                                              25,269             29,813
 Biological and agricultural assets                                       27,586             25,780
 Trade and other receivables                                              59,795             56,377
 Cash and cash equivalents                                                36,525             36,399
                                                                          149,175            148,369
 Assets held for sale                                              10     850                -
 Current assets                                                           150,025            148,369
 Total assets                                                             471,295            526,573
 Liabilities
 Trade and other payables                                                 (47,329)           (44,324)
 Loans and borrowings                                              11     (20,045)           (17,091)
 Corporation tax liability                                                (6,422)            (10,211)
 Provisions                                                               (1,280)            (1,631)
 Current liabilities                                                      (75,076)           (73,257)
 Loans and borrowings                                              11     (81,954)           (93,045)
 Other payables                                                           (6,842)            (8,996)
 Deferred tax                                                             (24,106)           (27,990)
 Provisions                                                               (700)              -
 Non-current liabilities                                                  (113,602)          (130,031)
 Total liabilities                                                        (188,678)          (203,288)
 Net assets                                                               282,617            323,285
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                     12     739                704
 Additional paid-in share capital                                  12     37,428             420,824
 Capital redemption reserve                                               5                  5
 Retained earnings                                                        183,489            (185,136)
 Hedging reserve                                                          (203)              (703)
 Foreign exchange reserve                                                 54,947             77,705
 Equity attributable to owners of the parent                              276,405            313,399
 Non-controlling interest                                                 6,212              9,886
 Total equity and reserves                                                282,617            323,285

 

 

The accompanying notes are an integral part of this consolidated financial
information.

                                                           Share     Additional paid-in share capital    Other       Hedging      Retained     Total attributable       Non-          Total

capital
reserves*
reserve
 earnings
 to equity holders of
controlling
equity

parent
interest
                                                           £000      £000                                £000        £000         £000         £000                     £000          £000

 As at 1 October 2022 (audited)                           704       420,824                             77,710      (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                             -         -                                   -           -            (23,146)     (23,146)                 1,582         (21,564)
 Other comprehensive income/(loss)                        -         -                                   (22,758)    500          -            (22,258)                 (717)         (22,975)
 Total comprehensive income/(loss) for the period         -         -                                   (22,758)    500          (23,146)     (45,404)                 865           (44,539)
 Contributions by and distributions to owners
 Share issue                                              35        12,985                              -           -            -            13,020                   -             13,020
 Share issue costs recognised through equity              -         (2,146)                             -           -            -            (2,146)                  -             (2,146)
 Cancellation of part of share premium account (note 10)  -         (394,235)                           -           -            394,235      -                        -             -
 Share-based payment                                      -         -                                   -           -            1,006        1,006                    -             1,006
 Total contributions by and distributions to owners       35        (383,396)                           -           -            395,241      11,880                   -             11,880
 Changes in ownership
 Acquisition of NCI                                       -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total changes in ownership interests                     -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total transactions with owners of the Company            35        (383,396)                           -           -            391,771      8,410                    (4,539)       3,871
 As at 30 September 2023 (unaudited)                      739       37,428                              54,952      (203)        183,489      276,405                  6,212         282,617

 As at 1 October 2021 (audited)                           670       400,682                             30,470      (5,876)      (154,231)    271,715                  7,884         279,599
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                             -         -                                   -           -            (32,087)     (32,087)                 1,636         (30,451)
 Other comprehensive income/loss)                         -         -                                   47,240      5,173        -            52,413                   366           52,779
 Total comprehensive income/(loss) for the period         -         -                                   47,240      5,173        (32,087)     20,326                   2,002         22,328
 Contributions by and distributions to owners
 Share issue                                              34        20,704                              -           -            -            20,738                   -             20,738
 Share issue costs recognised through equity              -         (562)                               -           -            -            (562)                    -             (562)
 Share-based payment                                      -         -                                   -           -            1,182        1,182                    -             1,182
 Total contributions by and distributions to owners       34        20,142                              -           -            1,182        21,358                   -             21,358
 Changes in ownership
 Total changes in ownership interests                     -         -                                   -           -            -            -                        -             -
 Total transactions with owners of the Company            34        20,142                              -           -            1,182        21,358                   -             21,358
 As at 30 September 2022 (audited)                        704       420,824                             77,710      (703)        (185,136)    313,399                  9,886         323,285

 

*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserves

                                                                       30 September  30 September 2022

2023
                                                                Notes  (unaudited)   (audited)
 Cash flows from operating activities
 Loss for the period                                                   (21,564)      (30,451)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment          8,453         8,602
 Depreciation and impairment of right-of-use assets                    10,260        11,293
 Other adjustments for non-cash items                                  -             (276)
 Amortisation and impairment of intangible fixed assets                18,495        19,161
 Profit on sale of property, plant and equipment                       (121)         (43)
 Loss on sale of discontinued operation                                3,774         -
 Finance income                                                        (2,802)       (319)
 Finance costs                                                         10,535        18,437
 Increase in fair value of contingent consideration receivable         -             (1,203)
 Share of loss of equity-accounted investees, net of tax               32            595
 Foreign exchange gains                                                (1,814)       (3,985)
 Share-based payment expense                                           1,006         1,182
 Tax expense                                                           3,365         7,274
 Increase in trade and other receivables                               (6,570)       (8,511)
 Decrease/(increase) in inventories                                    2,876         (5,406)
 Increase in biological and agricultural assets                        (1,659)       (6,099)
 Increase in trade and other payables                                  3,909         6,948
 Increase in provisions                                                386           1,058
                                                                       28,561        18,257
 Income taxes paid                                                     (8,556)       (7,447)
 Net cash flows generated from operating activities                    20,005        10,810
 Investing activities
 Acquisition of subsidiaries                                    15     (48)          -
 Purchase of investments in associates                                 (558)         (378)
 Receipts from disposal of subsidiaries                                1,250         1,544
 Purchases of property, plant and equipment                            (5,953)       (10,808)
 Purchase of intangibles                                               (196)         (205)
 Capitalised research and development costs                            (632)         (1,708)
 Proceeds from sale of fixed assets                                    227           220
 Cash receipts from swap contracts                                     11            -
 Interest received                                                     627           119
 Net cash flows used in investing activities                           (5,272)       (11,216)
 Financing activities
 Proceeds of share issues                                              13,020        20,737
 Share-issue costs recognised through equity                           (2,146)       (562)
 Acquisition of minority interests in subsidiaries              15     (8,009)       -
 Proceeds from bank or other borrowings                                21,847        67,939
 Repayment of bank or other borrowings                                 (18,470)      (74,874)
 Interest and finance charges paid                                     (9,131)       (9,629)
 Repayments of lease liabilities                                       (9,438)       (10,533)
 Net cash used in financing activities                                 (12,327)      (6,922)
 Net increase/(decrease) in cash and cash equivalents                  2,406         (7,328)
 Cash and cash equivalents at beginning of period                      36,399        39,460
 Effect of movements in exchange rate                                  (2,280)       4,267
 Cash and cash equivalents at end of period                            36,525        36,399

 

1.       Basis of preparation

 

Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the year ended 30 September 2023 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').

 

These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2022 were prepared in accordance with UK adopted
international accounting standards in conformity with the requirements of the
Companies Act 2006 as it applies to companies reporting under those standards
("Adopted IFRS") and are available from the Company's website at
www.benchmarkplc.com (http://www.benchmarkplc.com) .

 

The prior year comparatives are derived from audited financial information for
Benchmark Holdings plc Group as set out in the Annual Report and Accounts for
the year ended 30 September 2022 and the unaudited financial information in
the Quarterly Financial Report for the year ended 30 September 2022. The
comparative figures for the financial year ended 30 September 2022 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 30 November 2022 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not include a reference to any matters to which the
external auditor drew attention by way of emphasis without qualifying their
report, and (iii) did not contain a statement under section 498(2) or (3) of
the Companies Act 2006.

 

Statement of Compliance

 

These consolidated quarterly financial statements have been prepared in
accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These
financial statements do not include all of the information required for the
full annual financial statements and should be read in conjunction with the
Group's latest annual consolidated financial statements as at and for the year
ended 30 September 2023. These consolidated quarterly financial statements
were approved by the Board of Directors on 29 November 2023.

 

Going concern

 

The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.

 

As at 30 September 2023 the Group had net assets of £282.6m (30 September
2022: £323.3m), including cash of £36.5m (30 September 2022: £36.4m) as set
out in the consolidated balance sheet. The Group made a loss for the year from
continuing operations of £16.1m (year ended 30 September 2022: loss £28.7m),
and a loss for the year from discontinued operations of £5.5m (year ended 30
September 2022: loss £1.8m).

 

As noted in the Management Report, the business has performed steadily during
the year, showing resilience to some tough market conditions towards the end
of the year. The Directors have reviewed forecasts and cash flow projections
for a period of at least 12 months including downside sensitivity assumptions
in relation to trading performance across the Group to assess the impact on
the Group's trading and cash flow forecasts and on the forecast compliance
with the covenants included within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduction in short-term treatment capacity. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivities on sales growth in revenues and pressure on pricing on CIS
artemia in Advanced Nutrition. Mitigating measures within the control of
management have been identified should they be required in response to these
sensitivities, including reductions in areas of discretionary spend, tight
control over new hires, deferral of capital projects and temporary hold on
R&D for non-imminent products.

 

The refinancing exercise which commenced in FY22 was completed in Q1 FY23, so
that adequate finance facilities are in place, and with financial instruments
in place to fix interest rates and opportunities available to mitigate
globally high inflation rates, the Group continues to show resilience against
current global economic pressures.  The Directors are therefore confident
that even under all of the above sensitivity analysis, the Group has
sufficient liquidity and resources throughout the period under review whilst
still maintaining adequate headroom against the borrowing covenants. They
therefore remain confident that the Group has adequate resources to continue
to meet its liabilities as and when they fall due within the period of 12
months from the date of approval of these financial statements. Based on their
assessment, the Directors believe it remains appropriate to prepare the
financial statements on a going concern basis.

 

2.      Accounting policies

 

The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2023.

 

Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.

Alternative performance measures ('APMs')

The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU-adopted IFRS.
These APMs may not be directly comparable with other companies' APMs, and the
Directors do not intend these as a substitute for, or superior to, IFRS
measures.

Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 13).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.

Use of estimates and judgements

The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.

 

In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2023.

 

3.      Segment information

 

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

 

·      Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

·      Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

·      Health - the segment provides health products and services to the
global aquaculture market.

 

In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities.  This policy
was applied consistently throughout the current and prior period.

 

3.     Segment information (continued)

 

Reconciliations of segmental information to IFRS measures

  Segmental Revenue
  All figures in £000's    Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
(unaudited)
(unaudited)
(audited)
   Genetics                16,884        18,314        65,791        58,008
   Advanced Nutrition      17,111        18,872        78,503        80,286
   Health                  2,643         5,602         25,514        20,135
   Corporate               1,448         902           5,747         5,120
   Inter-segment sales     (1,472)       (932)         (5,811)       (5,272)
   Total                   36,614        42,758        169,744       158,277

 

 

  Segmental Adjusted EBITDA
  All figures in £000's        Q4 2023       Q4 2022      FY 2023        FY 2022

(unaudited)
(unaudited)
(unaudited)
(audited)
   Genetics                   5,073         5,473         14,409        15,980
   Advanced Nutrition         3,485         4,706         18,374        19,017
   Health                     (853)         625           4,772         108
   Corporate                  (613)         (2,046)       (3,317)       (3,924)
   Total                      7,092         8,758         34,238        31,181

 

 

  Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
 taxation
  All figures in £000's                                                  Q4 2023       Q4 2022      FY 2023        FY 2022

(unaudited)
(unaudited)
(unaudited)
(audited)
  Total reportable segment Adjusted EBITDA                              7,705         10,804        37,555        35,105
  Corporate Adjusted EBITDA                                             (613)         (2,046)       (3,317)       (3,924)
  Adjusted EBITDA                                                       7,092         8,758         34,238        31,181
  Exceptional - restructuring, acquisition and disposal related items   (4,599)       (423)         (7,817)       16
  Depreciation and impairment                                           (4,845)       (4,639)       (18,713)      (19,897)
  Amortisation and impairment                                           (4,265)       (5,440)       (18,495)      (19,161)
  Net finance costs                                                     (4,968)       (5,051)       (7,412)       (15,316)
  Loss before taxation                                                  (11,585)      (6,795)       (18,199)      (23,177)

 

  Reconciliation of segmental information to IFRS measures - Revenue and Loss
 before tax

  Revenue
                                                          Q4 2023       Q4 2022      FY 2023        FY 2022

(unaudited)
(unaudited)
(unaudited)
(audited)
  Total revenue per segmental information                36,614        42,758        169,744       158,277
  Less: revenue from discontinued operations             (23)          (310)         (268)         (570)
  Consolidated revenue                                   36,591        42,448        169,476       157,707

  Loss before tax
                                                          Q4 2023       Q4 2022      FY 2023        FY 2022

(unaudited)
(unaudited)
(unaudited)
(audited)
  Loss before tax per segmental information              (11,585)      (6,795)       (18,199)      (23,177)
  Less: loss before tax from discontinued operations     4,333         715           5,505         1,794
  Consolidated loss before tax                           (7,252)       (6,080)       (12,694)      (21,383)

 

 

4.     Revenue

 

The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2023. The Group's revenue is derived from
contracts with customers.

 

Disaggregation of revenue

 

In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).

 

Sale of goods and provision of services

 

                          3 months ended 30 September 2023 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           15,645      17,091                1,885      -            -                      34,621    23              34,598
  Provision of services   1,235       -                     758        -            -                      1,993     -               1,993
  Inter-segment sales     4           20                    -          1,448        (1,472)                -         -               -
                          16,884      17,111                2,643      1,448        (1,472)                36,614    23              36,591

                          3 months ended 30 September 2022 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           17,449      18,852                4,085      -            -                      40,386    310             40,076
  Provision of services   855         -                     1,517      -            -                      2,372     -               2,372
  Inter-segment sales     10          20                    -          902          (932)                  -         -               -
                          18,314      18,872                5,602      902          (932)                  42,758    310             42,448

                          12 months ended 30 September 2023 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           61,372      78,449                17,707     -            -                      157,528   268             157,260
  Provision of services   4,409       -                     7,807      -            -                      12,216    -               12,216
  Inter-segment sales     10          54                    -          5,747        (5,811)                -         -               -
                          65,791      78,503                25,514     5,747        (5,811)                169,744   268             169,476

                          12 months ended 30 September 2022 (audited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           53,978      80,191                13,528     -            -                      147,697   570             147,127
  Provision of services   3,973       -                     6,607      -            -                      10,580    -               10,580
  Inter-segment sales     57          95                    -          5,120        (5,272)                -         -               -
                          58,008      80,286                20,135     5,120        (5,272)                158,277   570             157,707

 

4.     Revenue (continued)

 

Primary geographical markets

 

 

                         3 months ended 30 September 2023 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
 Norway                  8,756       206                   1,990      -            -                      10,952    -               10,952
 Vietnam                 -           3,740                 -          -            -                      3,740     -               3,740
 India                   -           2,047                 -          -            -                      2,047     -               2,047
 Iceland                 3,205       -                     -          -            -                      3,205     -               3,205
 Ecuador                 -           1,749                 -          -            -                      1,749     -               1,749
 Canada                  879         23                    -          -            -                      902       -               902
 Turkey                  37          1,068                 -          -            -                      1,105     -               1,105
 Faroe Islands           1,172       -                     254        -            -                      1,426     -               1,426
 Greece                  -           790                   -          -            -                      790       -               790
 China                   106         477                   -          -            -                      583       -               583
 UK                      1,623       32                    42         -            -                      1,697     -               1,697
 Chile                   359         -                     357        -            -                      716       -               716
 Rest of Europe          321         749                   -          -            -                      1,070     -               1,070
 Rest of World           422         6,210                 -          -            -                      6,632     23              6,609
 Inter-segment sales     4           20                    -          1,448        (1,472)                -         -               -
                         16,884      17,111                2,643      1,448        (1,472)                36,614    23              36,591

 

 

                         3 months ended 30 September 2022 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
 Norway                  11,151      313                   4,204      -            -                      15,668    -               15,669
 Vietnam                 -           360                   -          -            -                      360       -               360
 India                   38          1,074                 -          -            -                      1,112     -               1,112
 Iceland                 1,975       1                     -          -            -                      1,976     -               1,976
 Ecuador                 -           2,606                 -          -            -                      2,606     -               2,606
 Canada                  542         -                     933        -            -                      1,475     -               1,475
 Turkey                  -           1,314                 -          -            -                      1,314     -               1,314
 Faroe Islands           1,539       2                     209        -            -                      1,750     -               1,750
 Greece                  -           931                   -          -            -                      931       -               931
 China                   158         1,199                 -          -            -                      1,357     -               1,357
 UK                      1,099       26                    33         -            -                      1,158     8               1,150
 Chile                   237         8                     222        -            -                      467       -               467
 Rest of Europe          184         844                   -          -            -                      1,028     -               1,028
 Rest of World           1,381       10,174                1          -            -                      11,556    302             11,253
 Inter-segment sales     10          20                    (0)        902          (932)                  -         -               -
                         18,314      18,872                5,602      902          (932)                  42,758    310             42,448

 

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

                         12 months ended 30 September 2023 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
 Norway                  39,008      899                   19,596     -            -                      59,503    -               59,503
 Vietnam                 -           11,087                -          -            -                      11,087    -               11,087
 India                   -           9,743                 -          -            -                      9,743     -               9,743
 Iceland                 7,343       -                     -          -            -                      7,343     -               7,343
 Ecuador                 38          7,257                 -          -            -                      7,295     -               7,295
 Canada                  3,071       96                    4,032      -            -                      7,199     -               7,199
 Turkey                  93          7,009                 -          -            -                      7,102     -               7,102
 Faroe Islands           6,160       -                     718        -            -                      6,878     -               6,878
 Greece                  -           6,759                 -          -            -                      6,759     -               6,759
 China                   327         4,502                 -          -            -                      4,829     -               4,829
 UK                      3,957       85                    177        -            -                      4,219     -               4,219
 Chile                   1,824       12                    991        -            -                      2,827     -               2,827
 Rest of Europe          1,470       4,879                 -          -            -                      6,349     -               6,349
 Rest of World           2,490       26,121                -          -            -                      28,611    268             28,343
 Inter-segment sales     10          54                    -          5,747        (5,811)                -         -               -
                         65,791      78,503                25,514     5,747        (5,811)                169,744   268             169,476

 

 

                         12 months ended 30 September 2022 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
 Norway                  34,666      967                   15,571     -            -                      51,204    -               51,204
 Vietnam                 32          10,512                -          -            -                      10,544    -               10,544
 India                   619         12,001                -          -            -                      12,620    -               12,620
 Iceland                 6,215       -                     -          -            -                      6,215     -               6,215
 Ecuador                 18          6,472                 -          -            -                      6,490     -               6,490
 Canada                  1,348       65                    2,907      -            -                      4,320     -               4,320
 Turkey                  -           6,419                 -          -            -                      6,419     -               6,419
 Faroe Islands           5,465       9                     587        -            -                      6,061     -               6,061
 Greece                  2           6,197                 -          -            -                      6,199     -               6,199
 China                   313         4,329                 -          -            -                      4,642     -               4,642
 UK                      4,318       93                    199        -            -                      4,610     54              4,556
 Chile                   1,006       15                    871        -            -                      1,892     -               1,892
 Rest of Europe          895         4,056                 -          -            -                      4,951     -               4,951
 Rest of World           3,054       29,056                -          -            -                      32,110    516             31,594
 Inter-segment sales     57          95                    -          5,120        (5,272)                -         -               -
                         58,008      80,286                20,135     5,120        (5,272)                158,277   570             157,707

 

5.     Discontinued operations

During the year, the group divested its Tilapia business for consideration of
USD 1 in a management buy out. Consequently, these

operations have been classified as discontinued in the current year with a
corresponding restatement of the consolidated income

statement and OCI for the year ended 30 September 2022 to reflect these
changes.

 

Summary of restatement of FY 2022 results as reported in FY 2022 financial
statements

 

                                                        Continuing operations         Discontinued operations
 All figures in £000's                                  Revenue      Adjusted EBITDA  Loss from continuing operations  Loss from discontinued operations
 As stated in financial year 2022 financial statements  158,277      31,181           (30,451)                         -
 Reclassified in Q1                                     (81)         269              361                              (361)
 As stated in Q1 2023 financial statements              158,196      31,450           (30,090)                         (361)
 Reclassified in Q2                                     (106)        267              359                              (359)
 As stated in Q2 2023 financial statements              158,089      31,717           (29,730)                         (721)
 Reclassified in Q3                                     (72)         266              359                              (359)
 As stated in Q3 2023 financial statements              158,017      31,984           (29,372)                         (1,079)
 Reclassified in Q4                                     (310)        622              721                              (721)
 As stated in Q4 2023 financial statements              157,707      32,606           (28,651)                         (1,800)

 

Results from discontinued operations

 

                                                 Q4 FY22            FY22
                                        Q4 FY23  Restated  FY23     Restated
                                        £000     £000      £000     £000
 Revenue                                23       310       268      570
 Cost of sales                          (217)    (730)     (973)    (1,372)
 Gross profit                           (194)    (420)     (705)    (802)
 Research and development costs         (42)     (37)      (59)     (57)
 Other operating costs                  (99)     (166)     (490)    (566)
 Adjusted EBITDA                        (335)    (623)     (1,254)  (1,425)
 Exceptional loss on disposal           (3,913)  -         (3,913)  -
 EBITDA                                 (4,248)  (623)     (5,167)  (1,425)
 Depreciation and impairment            (76)     (51)      (304)    (205)
 Operating loss / Loss before taxation  (4,324)  (674)     (5,471)  (1,630)
 Net finance costs                      (9)      (41)      (34)     (164)
 Loss before taxation                   (4,333)  (715)     (5,505)  (1,794)
 Tax on loss                            -        -         -        (6)
 Loss from discontinued operations      (4,333)  (715)     (5,505)  (1,800)

 

Exceptional items within discontinued operations

 

                                                Q4 FY22          FY22
                                       Q4 FY23  Restated  FY23   Restated
                                       £000     £000      £000   £000

 Loss on disposal of trade and assets  3,774    -         3,774  -
 Other costs relating to disposals     139      -         139    -
 Total exceptional loss on disposal    3,913    -         3,913  -

 

Results from discontinued operations by segment

The results from discontinued operations relate solely to the Genetics
operating segment.

 

 

6.     Exceptional items from continuing operations - restructuring,
acquisition and disposal related items

 

Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.

 

 

 All figures in £000's              Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)
Restated

(unaudited)
(audited)
 Acquisition related items          73            -             652           -
 Exceptional restructuring costs    645           1,668         3,470         1,229
 Disposal related items             (32)          (1,245)       (218)         (1,245)
 Total exceptional items            686           423           3,904         (16)

 

Acquisition related items comprise fees incurred in the year in connection
with an aborted acquisition.

 

Exceptional costs include: £2,598,000 (2022: £843,000) of legal and
professional costs in relation to preparing for listing the Group on the Oslo
stock exchange, and £872,000 (2022: £276,000) relating to restructuring
costs.

 

Disposal related items include a credit of £235,000 (2022: £1,203,000) in
relation to additional contingent consideration received and receivable from
disposals in previous years (£294,000 relating to the disposal of Aquaculture
UK on 7 February 2020, and £909,000 relating to the disposal of Improve
International Limited and its subsidiaries on 23 June 2020) together with
legal fees, lease costs and disposal items (net of proceeds received)
totalling £17,000 relating to additional costs and disposals proceeds
relating to disposals that occurred in 2020.

 

7.     Net finance costs

 

 All figures in £000's                                                 Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)
Restated

(unaudited)
(audited)
 Interest received on bank deposits                                    155           86            627           319
 Foreign exchange gains on financing activities                        -             7,133         158           4,422
 Foreign exchange gains on operating activities                        1,488         -             4,709         -
 Cash flow hedges - ineffective portion of changes in fair value       -             -             2,176         -
 Finance income                                                        1,643         7,219         7,670         4,741
 Leases (interest portion)                                             (383)         (988)         (1,620)       (1,580)
 Cash flow hedges - reclassified from OCI                              -             (2,546)       -             (2,546)
 Cash flow hedges - ineffective portion of changes in fair value       (1,547)       (2,753)       -             (4,475)
 Foreign exchange losses on operating activities                       (1,701)       (843)         (4,547)       (1,620)
 Foreign exchange losses on financing activities                       -             (898)         -             -
 Interest expense on financial liabilities measured at amortised cost  (2,971)       (4,201)       (8,881)       (9,672)
 Finance costs                                                         (6,602)       (12,229)      (15,048)      (19,893)
 Net finance costs recognised in profit or loss                        (4,959)       (5,010)       (7,378)       (15,152)

 

 

8.     Taxation

 

 All figures in £000's                                     Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)

(unaudited)                Restated

(audited)

 Analysis of charge in period
 Current tax:
 Current income tax expense on profits for the period      2,519         4,124         6,178         11,721
 Adjustment in respect of prior periods                    (880)         (39)          (880)         (39)
 Total current tax charge                                  1,639         4,085         5,298         11,682

 Deferred tax:
 Origination and reversal of temporary differences         319           (2,011)       (1,933)       (4,414)
 Deferred tax movements in respect of prior periods        -             -             -             -
 Total deferred tax charge/(credit)                        319           (2,011)       (1,933)       (4,414)
                                                                                                     -
 Total tax charge on continuing operations                 1,958         2,074         3,365         7,268

 

9.     Loss per share

 

Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

 

 

                                                            Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)
(audited)

(unaudited)
 Loss attributable to equity holders of the parent (£000)
 Continuing operations                                      (9,520)       (8,846)       (17,641)      (30,287)
 Discontinued operations                                    (4,333)       (715)         (5,505)       (1,800)
 Total                                                      (13,853)      (9,561)       (23,146)      (32,087)

 Weighted average number of shares in issue (thousands)     739,300       703,961       731,935       698,233

 Basic loss per share (pence)
 Continuing operations                                      (1.29)        (1.26)        (2.41)        (4.34)
 Discontinued operations                                    (0.59)        (0.10)        (0.75)        (0.26)
 Total                                                      (1.87)        (1.36)        (3.16)        (4.60)

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.

 

Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.

 

A total of 8,948,132 (2022: 6,240,304) potential ordinary shares have not been
included within the calculation of statutory diluted loss per share for the
period as they are anti-dilutive and reduce the loss per share. However, these
potential ordinary shares could dilute earnings per share in the future. The
diluted and basic loss per share are the same for both continuing and
discontinued.

 

10.   Assets held for sale

 

During the year, management committed to sell certain property, plant and
equipment with a market value of £850,000 which is held within the Health
business area.

 

                                    Transferred to held for sale  Fair value adjustment  Total assets transferred
 All figures in £000's
 Property, plant and equipment      850                           -                      850
 Total Assets held for sale         850                           -                      850

 

 

11. Loans and borrowings

 

                               FY 2023      FY 2022
 All figures in £000's         (unaudited)  (audited)
 Non-Current
 2025 750m NOK Loan notes      57,604       61,976
 Bank borrowings               16,799       17,226
 Unamortised debt issue costs  (742)        (922)
 Lease liabilities             8,293        14,765
                               81,954       93,045
 Current
 Bank borrowings               9,320        5,569
 Unamortised debt issue costs  (842)        -
 Lease liabilities             11,567       11,522
                               20,045       17,091
 Total loans and borrowings    101,999      110,136

 

The holders of ordinary shares are entitled to one vote per share at meetings
of the company, and to receive dividends from time

to time as declared.

 

At 30 September 2023 the fair value of the unsecured floating rate listed
green bond of NOK 750m was NOK 791m.

 

On 21 November 2022, the Group refinanced its USD15m RCF with a secured GBP20m
RCF provided by DNB Bank ASA, maturing

on 27 June 2025. The margin on this facility is a minimum of 2.75% and a
maximum of 3.25%, dependent upon the leverage of the

Group above the relevant risk free reference or IBOR rates depending on which
currency is drawn.

 

Benchmark Genetics Salten AS had the following loans (which are ring-fenced
debt without recourse to the remainder of the

Group) at 30 September 2023:

·      Term loan with a balance of NOK 171.9m provided by Nordea Bank
Norge Abp. The loan is a five-year term loan maturing no later than January
2028 at an interest rate of 2.5% above three-month NIBOR. This loan refinanced
the previous term loan from the same bank when the outstanding balance of NOK
162 million was repaid in February 2023.

•      NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2023 (2022: undrawn).

•      Term loan with a balance of NOK 35.5m (2022: NOK 40.1m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2023 was 7.45%. The
interest rate on this loan is variable.

•      A new term loan with a balance of NOK 10.0m provided by
Innovasjon Norge. The loan is a 15-year term loan maturing in July 2038. The
interest rate on this loan at 30 September 2023 was 7.45%. The interest rate
on this loan is variable.

•      NOK 21.75m loan provided by Salten Stamfisk AS (the minority
shareholder). The loan attracts interest at 2.5% above three month NIBOR and
is repayable on maturity of the Nordea term loan above.

 

The lease liabilities are secured on the assets to which they relate.

12.   Share capital and additional paid-in share capital

 

 

                                                    Number       Share Capital  Additional paid-in

share capital
 Allotted, called up and fully paid                              £000           £000
 Ordinary shares of 0.1 pence each
 Balance at 30 September 2022                       703,960,798  704            420,824
 Exercise of share options                          202,242      -              -
 Shares issued through placing and open offer       35,189,350   35             10,839
 Cancellation of part of the share premium account  -            -              (394,235)
 Balance at 30 September 2023                       739,352,390  739            37,428

 

The holders of ordinary shares are entitled to one vote per share at meetings
of the company, and to receive dividends from time to time as declared.

 

During the year ended 30 September 2023, the Group issued a total 202,242
ordinary shares of 0.1p each to certain employees of the Group relating to
share options, all of which were exercised at a price of 0.1pence.

 

On 15 December 2022, the Company issued 35,189,350 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 37.0
pence per share. Gross proceeds of £13.0m were received for the placing and
subscription shares. Non-recurring costs of £2.1m were in relation to the
share issue and this has been charged to the share premium account (presented
within additional paid-in share capital).

 

The share premium account is used to record the aggregate amount of value of
the premiums paid when the Company's shares are issued/redeemed at a premium.
On 20 March 2023, part of the Company's share premium account was cancelled
following the confirmation of the capital reduction by the High Court of
England and Wales on 14 March 2023 and the subsequent registration of the
court order with the Registrar of Companies. The capital reduction created
additional distributable reserves to the value of £394,235,072.

 

During the year ended 30 September 2022, the Group issued a total of 184,694
ordinary shares of 0.1p each to certain employees of the Group relating to
share options, of which 12,509 were exercised at a price of 0.1 pence, 172,185
were exercised at a price of 42.5 pence.

 

13.   Alternative performance measures and other metrics

 

Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.

 

Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.

 

Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.

 

Adjusted Operating Profit is operating profit before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.

 

Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.

13.    Alternative performance measures and other metrics (continued)

 

Reconciliation of Adjusted Operating Profit to Operating Loss

 

 All figures in £000's                                                             Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)

(unaudited)                Restated

(audited)
 Revenue                                                                           36,591        42,448        169,476       157,707
 Cost of sales                                                                     (16,674)      (17,895)      (82,726)      (73,777)
 Gross profit                                                                      19,917        24,553        86,750        83,930
 Research and development costs                                                    (1,592)       (1,991)       (6,069)       (6,634)
 Other operating costs                                                             (10,865)      (13,124)      (45,157)      (44,095)
 Depreciation and impairment                                                       (4,769)       (4,588)       (18,409)      (19,692)
 Amortisation of capitalised development costs                                     (604)         (615)         (2,437)       (2,165)
 Share of loss of equity accounted investees net of tax                            (33)          (57)          (32)          (595)
 Adjusted operating profit                                                         2,054         4,178         14,646        10,749
 Exceptional - restructuring, acquisition and disposal related items               (686)         (423)         (3,904)       16
 Amortisation and impairment of intangible assets excluding development costs      (3,661)       (4,825)       (16,058)      (16,996)
 Operating loss                                                                    (2,293)       (1,070)       (5,316)       (6,231)

 

Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax

 All figures in £000's                                                             Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)

(unaudited)                Restated

(audited)

 Loss before taxation                                                              (7,252)       (6,080)       (12,694)      (21,383)
 Exceptional - restructuring, acquisition and disposal related items               686           423           3,904         (16)
 Amortisation and impairment of intangible assets excluding development costs      3,661         4,825         16,058        16,996
 Adjusted (loss)/profit before tax                                                 (2,905)       (832)         7,268         (4,403)

 

Other Metrics

 All figures in £000's                                                   Q4 2023       Q4 2022       FY 2023       FY 2022

(unaudited)
Restated
(unaudited)

(unaudited)                Restated

(audited)
 Total R&D Investment
 Research and development costs
 - Continuing operations                                                 1,592         1,991         6,069         6,634
 - Discontinued operations                                               42            37            59            57
 Internal capitalised development costs                                  252           112           632           1,708
 Total R&D investment                                                    1,886         2,140         6,760         8,399

 All figures in £000's                                                    Q4 2023       Q4 2022      FY 2023        FY 2022

(unaudited)
Restated
(unaudited)

(unaudited)                Restated

(audited)
 Adjusted EBITDA excluding fair value movement in biological assets
 Adjusted EBITDA                                                         7,427         9,381         35,492        32,606
 Exclude fair value movement                                             1,807         848           103           (1,595)
 Adjusted EBITDA excluding fair value movement in biological assets      9,234         10,229        35,595        31,011

 

13.  Alternative performance measures and other metrics (continued)

 

Liquidity

 

A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.

 

                              30 September 2023  30 September 2022
 All figures in £000's        (unaudited)        (audited)
 Cash and cash equivalents    36,525             36,399
 Undrawn bank facility        12,250             9,398
 Liquidity                    48,775             45,797

 

The undrawn bank facility relates to the RCF facility.  At 30 September 2023,
£7.8m of the RCF was drawn (30 September 2022: £4m), leaving £12.3m undrawn
(30 September 2022: £9.4m).

 

14.   Net debt

Net debt is cash and cash equivalents less loans and borrowings.

                                                                     30 September 2023  30 September 2022
 All figures in £000's                                               (unaudited)        (audited)
 Cash and cash equivalents                                           36,525             36,399
 Loans and borrowings (excluding lease liabilities) - current        (8,478)            (5,569)
 Loans and borrowings (excluding lease liabilities) - non-current    (73,661)           (78,280)
 Net debt excluding lease liabilities                                (45,614)           (47,450)
 Lease liabilities - current                                         (11,567)           (11,522)
 Lease liabilities - non-current                                     (8,293)            (14,765)
 Net debt                                                            (65,474)           (73,737)

 

 

15.   Business combinations and transactions in subsidiary companies

In June, the Group acquired 66% of the issued share capital of Baggfossen
Mikrokraft AS to bring the total owned to 100% for consideration of £48,000.
The goodwill has been impaired in the period. The following table shows the
consideration paid and the fair value of the assets acquired.

 

                                                     Total
                                                     £000
 Consideration
 Cost of investment                                  48

 Satisfied by:
 Cash                                                48
 Total consideration                                 48

 Fair value of assets acquired
 Fixed assets                                        307
 Accounts Receivable                                 (13)
 Other receivables                                   1
 Financial instrument - interest rate swap           10
 Accounts payable                                    (1)
 Other current liabilities - advance from customers  (3)
 Bank loan                                           (235)
 Advance from Salten Stamfisk                        (10)
 Advance from BG Salten                              (12)
 Total identifiable net assets                       44
 Goodwill                                            4

 

On 15 February 2023, the Group purchased the minority interest's shareholding
of 14,981,272 shares in Benchmark Genetics Iceland HF for €9,000k
(£8,009k). Following this acquisition, Benchmark Genetics Limited, a
subsidiary of Benchmark Holdings plc, now owns 100% of the share capital of
Benchmark Genetics Iceland HF.

On 6 February 2023, the Group exercised the put/call option in place to
purchase the final 20% of Benchmark Genetics USA Inc for 1 NOK.

On 11 May 2023, the Group received £1,250,000 as the final part of the
deferred consideration for Improve International Limited and its subsidiaries
which was sold in June 2020.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR PPGGPGUPWUUB

Recent news on Benchmark Holdings

See all news